SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In MGT Capital Investments, Inc. To Contact The Firm Before Lead Plaintiff Deadline

NEW YORK, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in MGT Capital Investments, Inc. (“MGT Capital” or the “Company”) (NYSE MKT:MGT) of the November 21, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased MGT Capital stock or options between May 9, 2016, and September 20, 2016 (the “Class Period”).  The case, Exley v. MGT Capital Investments, Inc. et al, No. 1:16-cv-07415 was filed on September 22, 2016, and has been assigned to Judge Naomi Reice Buchwald.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose the conduct that led to a Securities and Exchange Commission (“SEC”) investigation. 

Specifically, on September 19, 2016, the Company announced that it had received an SEC subpoena requesting “certain information” on September 15, 2016.

After the announcement, MGT Capital’s share price fell from $3.26 per share on September 18, 2016 to a closing price of $2.52 on September 19, 2016—a $0.74 or a 22.70% drop.

Then, on September 20, 2016, MGT Capital issued a press release entitled “MGT Provides Update on Status of D-Vasive Acquisition.” Therein, the Company disclosed that the New York Stock Exchange informed the Company on September 19, 2016, that the NYSE would not approve the listing of the 43.8 million shares that the Company was required to issue in order to complete the closing of its D-Vasive merger.

After the announcement, MGT Capital’s share price fell from $2.52 per share on September 19, 2016 to a closing price of $1.89 on September 20, 2016—a $0.63 or a 25% drop.

Request more information now by clicking here: www.faruqilaw.com/MGT . There is no cost or obligation to you.

Take Action

If you invested in MGT Capital stock or options May 9, 2016, and September 20, 2016 and would like to discuss your legal rights, visit www.faruqilaw.com/MGT . You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com .  Faruqi & Faruqi, LLP also encourages anyone with information regarding MGT Capital’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.  Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP 685 Third Avenue, 26th Floor New York, NY 10017 Attn:  Richard Gonnello, Esq. rgonnello@faruqilaw.com Telephone: (877) 247-4292 or (212) 983-9330

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Peptide Therapy Rules Change: Gameday Ups the Ante

Updated Category News Views 110

Gameday Men's Health: Leading the Safe Peptide Charge Finally, we got some regulatory sanity stepping up to the plate with peptides. You see, the FDA's new interim policy is letting state-licensed compounding pharmacies work their magic with peptides, but only under strict medical watch. And Gameday Men's Health sure ain't wasting any time setting up shop in this fresh...

Continue Reading
Fidelis Care Opens $120K Workforce Grants for Aid

Updated Category News Views 112

Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...

Continue Reading
Chip Earnings Fuel Market Gains Amid Volatility Dip

Updated Category News Views 56

Tech Earnings Drive Market Resilience Amid a climate of economic uncertainty, it's refreshing to see semiconductor and tech earnings offering a little backbone to the market. This week, the S&P 500 climbed 1.51%, while the Nasdaq Composite jumped 1.98% over three sessions. It's like watching Rocky get up off the mat—those indices pushing higher when it seemed like they...

Continue Reading
Read/Write Labs Tackles Brain-Tech Fusion Ambitions

Updated Category News Views 88

Buck up, investors! There's a new player on the field marrying AI and neuroscience with some serious firepower and a respectable roster. Read/Write Labs—what you might've known yesterday as Dandelion Science—has kicked off under a fresh banner, amping up efforts to decode and recode our noggin's electrical orchestra. And with the likes of Jim DiCarlo, Dan Yamins, and...

Continue Reading
Fannie Mae Q3 2026 Earnings Surpass Expectations

Updated Category News Views 84

An Upward Trend in Fannie Mae's Financials Hold onto your hats—Fannie Mae's swinging into action with hefty third-quarter numbers that'd make most firms drool. The latest figures, disclosed in their 10-Q filing, boast a net income of $4.2 billion for Q3 2026. You heard me right, billion! Now, to a market vet, these aren't digits to scoff at. And as the economy keeps...

Continue Reading
Aktia Bank: Steady Ratings, Focused Expansion in Europe

Updated Category News Views 123

Aktia's Ratings Get a Boost In the world of financial minutiae, it was S&P Global Ratings that took the stage, buzzing about Aktia Bank Plc. The bank just had its ratings held steady with an outlook lift from negative to stable. That's like someone throwing you a life jacket when you're treading water; significant if you're trying to stay afloat, not so much if you've got...

Continue Reading
ESENTIA Lifts EBITDA, Reduces Debt, Eyes Expansion

Updated Category News Views 38

ESENTIA Flexes Financial Muscles: What's the Deal? Walk with me through the gritty world of financials, and you’ll see that ESENTIA’s latest figures are a mixed bag with a tantalizing upside. We're talking about adjusted EBITDA ticking up to a cool $86 million in the third quarter of '26, a 1.3% lift from last year. Not too shabby, eh? Especially when you're grappling...

Continue Reading
VeriSilicon's GLTiny: Game-Changer for Wearable Tech

Updated Category News Views 45

Revolutionizing Wearable Graphics with GLTiny There's a fresh breeze blowing through the world of wearable tech, and VeriSilicon's GLTiny seems to be at the heart of it. When the silicon giant out of Shanghai tossed GLTiny into the mix, it wasn't just throwing another chip on the barbie. Oh no, this is a real pivot towards juicing up those smart gadgets strapped to your...

Continue Reading
Ballard’s HPU Agile-H Poised to Transform Portable Energy

Updated Category News Views 76

Another Step Forward with Hydrogen Ballard's got another ace up its sleeve with the HPU Agile-H. Now here’s the kicker—everyone’s scrambling for cleaner, more portable energy solutions, and Ballard’s stepped up. Born from their acquisition of GeoPura, this lightweight hydrogen powerhouse is engineered for those spots rudely ignored by the grid. Place your bets on...

Continue Reading
Replay Sports Cards Nets STAR Award for Innovation

Updated Category News Views 82

A New Era for Franchise Onboarding Just when you think the sports card world couldn't get any more niche, along comes Replay Sports Cards thumping its chest with some serious innovation. This Charlotte-based franchise just snagged the Franchise Innovation Award from Franchise Update Media. Yep, they're the only ones getting tips of the hat for the Most Innovative...

Continue Reading

Top 5 Most Recently Viewed Articles

Sollis Health Welcomes Katy Marshall as Chief Growth Officer

Updated Category News Views 511

Sollis Health Welcomes Katy Marshall as Chief Growth Officer The leading concierge medical provider has appointed Katy Marshall as Chief Growth Officer. With her extensive background in driving growth for consumer and healthcare brands, she will guide the company's marketing, sales, and product strategies. Experienced Leadership Katy brings a wealth of experience to...

Continue Reading
Kulicke & Soffa Delivers Strong Q4 Performance Highlights

Updated Category News Views 153

Strong Financial Performance in Q4 Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC) reported impressive financial results for the fourth quarter, showcasing resilience and growth in a challenging market. The company achieved a net revenue of $177.6 million, reflecting its ongoing commitment to innovation and operational efficiency. Lester Wong, the Interim Chief...

Continue Reading
Unlocking Dividend Income: Strategies for Salesforce Investors

Updated Category News Views 85

Understanding Salesforce's Dividend Potential Salesforce, Inc. (NYSE: CRM) is a leading company known for its innovative cloud-based solutions. With its upcoming fourth-quarter financial results, many investors are curious about how to maximize their returns, particularly through dividends. This approach can be an excellent way to create a significant income stream while...

Continue Reading
Investigation Launched into Sage Therapeutics' Recent Drug Trials

Updated Category News Views 93

Introducing Sage Therapeutics Sage Therapeutics, Inc. (NASDAQ: SAGE) is a biopharmaceutical company dedicated to developing innovative therapies aimed at enhancing brain health. However, recent events have raised serious concerns among investors, prompting an investigation into possible violations of federal securities laws. Stock Price Affected by Recent Events FDA...

Continue Reading
Genius Group Investors Can Pursue Class Action for Losses

Updated Category News Views 208

Genius Group Limited Faces Class Action Lawsuit Genius Group Limited, recognized by its ticker symbol GNUS, is currently embroiled in a class action lawsuit aimed at addressing significant investor losses. This legal action comes as a response to alleged stock market misconduct by certain trading firms. Investors Encouraged to Take Action The law firm Bronstein, Gewirtz &...

Continue Reading